Roche News, Roche Quote, RHHBY Quote

Roche (OP:RHHBY) Delayed: 59.11 +1.97 (3.45%)

Prev. Close

$57.14

Today 6M 1Y 5Y

Open

$58.53

52 Wk High

$35.13

52 Wk Low

$28.10

Day High

$59.21

Day Low

$58.52

P/E

N/A

EPS

$0.00

Volume

1,502,699

Friends, Peers and Foes (?): RO, ROG, ROG:SW, ROP, CHGCY (more...)

ALERTS | RSS

Oct 19, 2026 09:31 AM RBC Capital on Roche Holding (ROG:SW) (RHHBY): 'Strong momentum into 3Q26 could make for a tricky set-up'
Oct 19, 2026 01:01 AM Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio
Oct 16, 2026 01:00 AM FDA approves Genentech's Enspryng for thyroid eye disease
Oct 16, 2026 01:00 AM FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
Oct 10, 2026 05:40 PM Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
Oct 9, 2026 01:01 AM FDA approves Genentech's Tecentriq for stage III colon cancer
Oct 9, 2026 01:01 AM FDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
Oct 7, 2026 01:00 AM Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRC
Oct 1, 2026 09:00 AM Flatiron Health's Breast Cancer Panoramic Dataset Surpasses One Million Patients, Enabling Real-World Research at Unprecedented Scale
Oct 1, 2026 07:00 AM Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends

Entities mentioned with RHHBY

View All Entities